English
Regional settings| Spread | 0.35 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ CHF 5,000.00 Short position overnight fee ~ CHF 4,000.00 | -0.014982% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ CHF 5,000.00 Short position overnight fee ~ CHF 4,000.00 | -0.00724% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | CHF | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Switzerland | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 40.9 |
| Open | 40.85 |
| 1-Year Change | -9.42% |
| Day's Range | 40.5 - 41.3 |
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
BRIEF: For the fiscal year ended 31 December 2021, BB BIOTECH AG revenues decreased from SF741.8M to -SF343.6M. Net loss totaled SF404.8M vs. income of SF691.2M. Revenues reflect Unrealized Gains/Losses on Securities decrease from SF460.9M to -SF652.2M, Dividend Income decrease from SF243K to SF0K, Other income decrease of 83% to SF4K. Net loss reflects Management fees increase of 27% to SF50.7M (expense).
3/2016, 5-for-1 stock split (Factor: 5).
